Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 15/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11895664 | 0.91 | AHCY (0.50) | AHCYHDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL1197730 | 0.88 | AHCY (0.50) | AHCYHDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL1197505 | 0.84 | AHCY (0.51) | AHCYNAMPT | |
| SCHEMBL1026979 | 0.83 | HDAC1 (0.38) | AHCYHDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL11896028 | 0.81 | AHCY (0.53) | AHCYNAMPT | |
| Hydrochloric Acid SCHEMBL1026614 | 0.81 | AHCY (0.43) | AHCYHDAC1HDAC3HDAC2NAMPT | |
| SCHEMBL1027354 | 0.81 | HDAC1 (0.38) | AHCYHDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL11895333 | 0.79 | AHCY (0.63) | AHCY | |
| SCHEMBL11975054 | 0.79 | AHCY (0.56) | AHCYNAMPT | |
| SCHEMBL1024460 | 0.78 | AHCY (0.38) | AHCYNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | BHMT, CBS, BHMT2 | AHCY 4/4885HDAC1 1765/4885HDAC3 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.